GlobeNewswire BiotechnologyQwen · 实盘不做把握 1/10不做原因:不是事件🔁 +1 同一事件
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:01:40·⚡ 决策 09-01 20:10:54 +9m14s·56.3 天前
CytomX Therapeutics宣布管理层将参加9月三场投资者会议（Wells Fargo、Cantor、Morgan Stanley）
该公告仅为CytomX管理层参加三场常规医疗健康投资者会议的日程通知，不含任何新临床数据、合作进展、监管动态、财务指引或管线更新。投资者会议参会是上市公司标准IR活动，不构成价格催化，无任何方向性增量信息。
📄 原文GlobeNewswire Biotechnology↗ 原文
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in t…
不做 CytomX Therapeutics（CTMX.US）
例行投资者会议参会日程公告，无任何新增临床数据、合作、监管或财务信息，不构成可交易催化，无方向性增量
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CytomX于2026-09-01通过GlobeNewswire发布投资者会议参会日程，宣布管理层将在9月8日、9日和14日分别出席Wells Fargo、Cantor和Morgan Stanley的医疗健康会议。公告全文无任何新信息（无临床数据、无新合作、无监管进展、无财务指引变化），仅为标准IR日程通知。此类公告不构成可交易催化，历史上也不会引发股价异动。结论：无事件、无增量、无方向，不做。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例即可判定不做：事件本身无增量信息
方向:无适用先例——投资者会议参会公告不构成可交易事件类别
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 888 ms
{"result": "search_processed_events:agent query=`ctmx conference presentation wells fargo cantor morgan stanley | cytomx therapeutics investor conference september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 62.4/72 小时、2202 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 3,005 字
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
Wells Fargo 21
st
Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat: 2:15 p.m. ET
Location: Boston, MA
2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Fireside Chat: 10:20 a.m. ET
Location: New York, NY
Morgan Stanley 24
th
Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Fireside Chat: 1:50 p.m. ET
Location: New York, NY
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at
www.cytomx.com
. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY
®
therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY
®
cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit
www.cytomx.com
and follow us on
LinkedIn
and
X
(formerly Twitter)
.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
Wells Fargo 21
st
Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat: 2:15 p.m. ET
Location: Boston, MA
2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Fireside Chat: 10:20 a.m. ET
Location: New York, NY
Morgan Stanley 24
th
Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Fireside Chat: 1:50 p.m. ET
Location: New York, NY
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at
www.cytomx.com
. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY
®
therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY
®
cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit
www.cytomx.com
and follow us on
and
X
(formerly Twitter)
.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。